Get the Stockscreener App
8.49
3.41%
0.28
After Hours:
8.25
-0.24
-2.83%
Immuneering Corp stock is traded at $8.49, with a volume of 858.32K.
It is up +3.41% in the last 24 hours and up +161.23% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$8.21
Open:
$8.07
24h Volume:
858.32K
Relative Volume:
0.58
Market Cap:
$308.35M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-4.4921
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
+54.08%
1M Performance:
+161.23%
6M Performance:
+458.55%
1Y Performance:
+493.71%
1-Day Range:
$7.97
$8.5899
1-Week Range:
$5.465
$9.37
52-Week Range:
$1.10
$9.37
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
8.49 | 338.38M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
What MACD and RSI say about Immuneering CorporationTrade Volume Summary & Advanced Technical Analysis Signals - Newser
Will Immuneering Corporation rebound enough to break evenJuly 2025 EndofMonth & Reliable Volume Spike Alerts - Newser
Signal strength of Immuneering Corporation stock in tech scannersWeekly Trend Report & Capital Efficiency Focused Strategies - Newser
What candlestick patterns are forming on Immuneering CorporationTrade Risk Report & Expert Approved Momentum Trade Ideas - Newser
Detecting support and resistance levels for Immuneering Corporation2025 Breakouts & Breakdowns & Verified Momentum Stock Alerts - Newser
Can Immuneering Corporation recover in the next quarter2025 Analyst Calls & Momentum Based Trading Signals - Newser
Immuneering to announce updated data from Phase 2a trial of Atebimetinib + mGnP - MSN
Volume spikes in Immuneering Corporation stock – what they mean2025 Trading Volume Trends & Daily Chart Pattern Signal Reports - Newser
Published on: 2025-09-11 02:15:14 - Newser
Can trapped investors hope for a rebound in Immuneering Corporation2025 Breakouts & Breakdowns & High Accuracy Swing Trade Signals - Newser
Oppenheimer reiterates Outperform rating on Immuneering stock ahead of data - Investing.com
Immuneering Corporation to Host Investor Call and Present Updated Data at Upcoming Scientific Conferences - Quiver Quantitative
Immuneering to present updated pancreatic cancer survival data - Investing.com
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 - GlobeNewswire Inc.
Strategies to average down on Immuneering CorporationWeekly Stock Summary & Smart Money Movement Alerts - Newser
What earnings revisions data tells us about Immuneering CorporationDay Trade & Free Risk Controlled Daily Trade Plans - Newser
How to integrate Immuneering Corporation into portfolio analysis toolsJuly 2025 Closing Moves & Safe Entry Point Identification - Newser
Understanding Immuneering Corporation’s price movementJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser
Backtesting results for Immuneering Corporation trading strategies2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
Combining price and volume data for Immuneering CorporationWatch List & Verified Momentum Stock Alerts - Newser
How hedge fund analytics apply to Immuneering Corporation stockEarnings Overview Report & Safe Investment Capital Preservation Plans - Newser
Has Immuneering Corporation found a price floorMarket Performance Summary & Weekly High Conviction Ideas - Newser
Can Immuneering Corporation expand into new marketsEarnings Miss & Growth-Oriented Investment Plans - خودرو بانک
What is the dividend yield of Immuneering CorporationMarket Activity Recap & Weekly Return Optimization Plans - خودرو بانک
Using Python tools to backtest Immuneering Corporation strategiesJuly 2025 Pullbacks & Weekly Top Gainers Alerts - Newser
Tick level data insight on Immuneering Corporation volatilityJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - Newser
Custom watchlist performance reports with Immuneering CorporationTrade Risk Summary & Free Growth Oriented Trading Recommendations - Newser
Aug Reactions: Will Immuneering Corporation stock recover after earningsQuarterly Performance Summary & Technical Confirmation Trade Alerts - خودرو بانک
Can Immuneering Corporation ride the EV waveJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - خودرو بانک
Immuneering Corporation (IMRX) files for up to 9.18M share offering by selling stockholders - StreetInsider
Buyback Watch: Can Immuneering Corporation deliver consistent dividends2025 Growth vs Value & Verified Swing Trading Watchlist - خودرو بانک
Can a trend reversal in Immuneering Corporation lead to recoveryJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - Newser
Order flow analysis tools used on Immuneering CorporationWeekly Gains Summary & High Conviction Trade Alerts - Newser
Building trade automation scripts for Immuneering CorporationBreakout Watch & Safe Swing Trade Setups - Newser
What momentum shifts mean for Immuneering CorporationRisk Management & Technical Pattern Alert System - Newser
Is Immuneering Corporation a cyclical or defensive stockShort Setup & Growth Oriented Trading Recommendations - خودرو بانک
Does Immuneering Corporation show high probability of reboundShare Buyback & Daily Oversold Bounce Ideas - Newser
Needham & Company LLC Reiterates "Buy" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):